Bicara Therapeutics (NASDAQ:BCAX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Bicara Therapeutics (NASDAQ:BCAX) had its price target upped by HC Wainwright from $40.00 to $42.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 104.88% from the company’s previous close.

BCAX has been the subject of several other reports. Wedbush reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. Citigroup started coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They set an “outperform” rating on the stock. Citizens Jmp initiated coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They issued a “market perform” rating and a $31.00 price target for the company. BTIG Research restated a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Finally, Mizuho raised Bicara Therapeutics to a “hold” rating in a research report on Thursday, December 18th. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $28.00.

Bicara Therapeutics Stock Up 3.1%

Shares of Bicara Therapeutics stock opened at $20.50 on Tuesday. The company has a market cap of $1.34 billion, a PE ratio of -8.10 and a beta of -1.24. The business has a 50 day moving average of $17.28 and a 200 day moving average of $16.69. Bicara Therapeutics has a 52 week low of $7.80 and a 52 week high of $21.05.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.04. On average, research analysts anticipate that Bicara Therapeutics will post -2.59 earnings per share for the current year.

Insider Buying and Selling at Bicara Therapeutics

In other news, insider David Raben sold 16,300 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $18.52, for a total value of $301,876.00. Following the sale, the insider directly owned 55,286 shares of the company’s stock, valued at $1,023,896.72. This represents a 22.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Ivan Hyep sold 9,200 shares of the company’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $18.52, for a total transaction of $170,384.00. Following the completion of the sale, the chief financial officer directly owned 145,355 shares in the company, valued at $2,691,974.60. This represents a 5.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 137,969 shares of company stock worth $2,586,198. Corporate insiders own 15.50% of the company’s stock.

Institutional Investors Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bleakley Financial Group LLC bought a new position in shares of Bicara Therapeutics during the third quarter valued at approximately $481,000. Cantor Fitzgerald L. P. purchased a new position in shares of Bicara Therapeutics during the third quarter valued at approximately $1,579,000. Schroder Investment Management Group boosted its position in shares of Bicara Therapeutics by 921.0% in the 2nd quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock worth $3,951,000 after purchasing an additional 383,681 shares in the last quarter. Skandinaviska Enskilda Banken AB publ grew its stake in shares of Bicara Therapeutics by 160.9% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 99,236 shares of the company’s stock worth $922,000 after buying an additional 61,201 shares during the last quarter. Finally, SCS Capital Management LLC purchased a new stake in shares of Bicara Therapeutics in the 2nd quarter worth approximately $496,000.

Trending Headlines about Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Wall Street analyst consensus implies a large upside (~54.9%) to BCAX based on average price targets and improving earnings-estimate revisions, a factor traders cite as justification for buying interest. Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here’s is How to Trade
• Positive Sentiment: Clinical progress: Seeking Alpha reiterates a Buy rating as BCAX advances its pivotal phase 3 FORTIFI-HN01 study; strong phase 1/1b signals (12‑month OS 61%, ORR 54% with ficerafusp alfa + KEYTRUDA) support the program. Key upcoming catalysts: phase‑3 interim readout mid‑2027 and long‑term phase 1b follow‑up at ASCO 2026. Near‑full enrollment expected by year‑end. Bicara: Maintaining ‘Buy’ Rating On Ficerafusp Alfa Phase 3 Advancement
• Positive Sentiment: Q4 / cash position: Earnings call highlights show a stronger cash position and a slight beat on Q4 EPS vs. estimates, which reduces near‑term dilution risk and supports runway for clinical execution. Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full Q4 earnings call transcript is available for investors digging into management comments on timelines and cash burn; useful for detailed diligence but not a single price driver by itself. Q4 2025 earnings call transcript
• Negative Sentiment: Mixed analyst views: Goldman Sachs raised its PT to $16 (neutral) and Wells Fargo to $16 (equal‑weight)—both targets sit well below the current market price, implying downside from their perspective. These conservative calls can cap near‑term upside and add volatility. Benzinga coverage of analyst moves
• Positive Sentiment: Other broker support remains bullish: Wedbush (outperform, $30 PT), Citizens Jmp (market outperform, $31 PT) and HC Wainwright (buy, PT $42) provide higher upside scenarios that likely underlie investor optimism. Benzinga coverage of analyst moves

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.